Aprotinin: Designing Protease-Controlled Assays
2026-09-17
Aprotinin, or bovine pancreatic trypsin inhibitor, is more than a fibrinolysis inhibitor: it is a reversible perturbation tool for separating protease-driven effects from assay artifacts. This guide integrates cardiovascular research, inflammatory readouts, and GRO-seq-informed experimental design.
How Impending Cell Death Generates Metastatic States
2026-09-16
Conod, Silvano, and Ruiz i Altaba show that tumor cells surviving an impending-death experience can become stable prometastatic cells, termed PAMEs, rather than simply returning to a pre-treatment state. Their study links PAME formation to ER stress, PERK-CHOP signaling, GLI and NANOG-associated reprogramming, and a cytokine-mediated interaction with neighboring PIM cells.
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-09-16
This FASEB Journal study developed chemically modified p21 mRNA–loaded lipid nanoparticles for localized intravesical treatment of bladder cancer. The work links restored nuclear p21 expression to cell-cycle inhibition, DNA-damage signaling, apoptosis, and tumor suppression in an orthotopic mouse model, while highlighting the translational value of bladder-directed delivery.
Protease Inhibitor Cocktail: Protecting Assay Truth
2026-09-15
Discover how the Protease Inhibitor Cocktail supports reliable protein extraction, phosphorylation-sensitive assays, Western blotting, and co-immunoprecipitation. This article connects pre-analytical protein preservation with insights from a recent melatonin-hydrogel study in atopic dermatitis.
Sulfo-NHS-SS-Biotin: Practical Labeling Guide
2026-09-15
Sulfo-NHS-SS-Biotin is a water-compatible, amine-reactive reagent for labeling accessible primary amines on proteins and cell-surface molecules, with a reducible disulfide bond for label removal. It is suitable for controlled biotinylation, affinity capture, and detection, but should not be treated as a stable aqueous stock or assumed to label intracellular proteins in intact cells.
Sulfo-NHS-SS-Biotin: Practical Labeling Guide
2026-09-14
Sulfo-NHS-SS-Biotin is a water-compatible, amine-reactive reagent for labeling proteins and accessible cell-surface primary amines with a cleavable biotin handle. It is suitable for affinity capture and reversible protein purification, but not for intracellular labeling in intact cells or workflows that require a permanently attached biotin tag.
Peptidisc-Assisted Nanobody Clustering
2026-09-14
The reference preprint introduces peptidisc-assisted hydrophobic clustering as a way to assemble nanobodies into soluble multimeric, bispecific, and autofluorescent proteins. By coupling nanobodies to a transmembrane segment and stabilizing the resulting associations with peptidisc, the study uses avidity to improve target recognition while expanding protein-engineering options beyond tandem fusion and scaffold-based assembly.
Protease Inhibitor Cocktail for Reliable Cell Assays
2026-09-13
This scenario-driven guide explains how Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO), SKU K1010, can stabilize protein measurements associated with cell viability, proliferation, and cytotoxicity experiments. It covers EDTA compatibility, 1:100 use, workflow controls, vendor-selection criteria, and limitations when interpreting phosphorylation or T-cell signaling data.
Cyanidin Chloride for Reliable Cell Assays
2026-09-12
This scenario-based guide explains how Cyanidin Chloride (SKU N2525) can be integrated into oxidative stress, viability, proliferation, and cytotoxicity workflows. It emphasizes identity control, solvent compatibility, assay-interference controls, and evidence-based interpretation for more reproducible laboratory decisions.
Viperin Targets Coronavirus nsp8 to Disrupt RTC Assembly
2026-09-11
The reference study identifies a nonenzymatic antiviral role for viperin: direct binding to coronavirus nsp8 destabilizes replication-transcription complex assembly and reduces RNA-dependent RNA polymerase activity. Using porcine deltacoronavirus as a model, the work separates this protein-interaction mechanism from ddhCTP-mediated RNA chain termination and highlights nsp8 as a possible broad-spectrum antiviral target.
AR Heterogeneity Shapes Enzalutamide Response in PCa
2026-09-11
The reference study shows that androgen receptor heterogeneity is not merely a descriptive feature of advanced prostate cancer: nuclear AR-positive and AR-low or AR-negative cell populations exhibit different tumor behavior and treatment responses. By combining patient tissue profiling, engineered LNCaP models, xenografts, transcriptomics, and combination therapy experiments, the authors identify BCL-2 as a candidate vulnerability for AR-low castration-resistant disease.
JSH-23: A Practical NF-κB Inhibitor Guide
2026-09-10
JSH-23 offers a focused way to test NF-κB p65 nuclear localization and transcriptional activity without directly preventing IκB degradation. This guide connects macrophage assays, cytokine profiling, and a cisplatin-induced acute kidney injury model with practical dosing, controls, and troubleshooting strategies.
Mycophenolic Acid: Reading Immunometabolic Assays
2026-09-10
Mycophenolic acid is more than a dehydrogenase inhibitor: it is a mechanistic probe for connecting nucleotide metabolism with immune-cell behavior. This guide explains how to interpret whole-blood stimulation results, control experimental confounding, and select meaningful orthogonal readouts.
EZ Cap™ Firefly Luciferase mRNA Workflow
2026-09-09
Build cleaner delivery, translation, viability, and imaging experiments with a Cap1- and poly(A)-optimized luciferase transcript. This workflow also shows how to use the reporter as an orthogonal control when studying sequence-dependent innate immune responses to intracellular ssDNA.
CSBTA Pharmacokinetics in MASH Mice
2026-09-09
This 2025 reference study integrates pharmacokinetics, tissue distribution, transporter biology, and metabolic enzyme analysis to explain how MASH alters exposure to Corydalis saxicola Bunting total alkaloids. Its findings suggest that disease-state-dependent changes in Cyp450s, Oatp1b2, P-glycoprotein, and PXR signaling may affect hepatic accumulation and dosage interpretation.